AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
25 7월 2023 - 5:01AM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative
medical technology company focused on restoring healthy blood flow
in the body’s vascular system, expanding cancer treatment options,
and improving quality of life for patients, today announced the
appointment of Lorinda Burgess to the Company’s Board of
Directors.
Ms. Burgess brings over 35 years of management, financial, and
global operations experience, including over 15 years at Medtronic,
Inc., where she was responsible for the company’s Americas Region
as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess
led optimization initiatives that drove operational efficiencies
and significant cost reductions.
“Ms. Burgess’ impressive career has been marked by her ability
to shape and execute transformative strategies that drive growth
and remarkable profitability,” said Jim Clemmer, AngioDynamics
President and CEO. “Her extensive track record of strong leadership
and operational excellence adds to the collective expertise of our
Board, and we are eager to benefit from her insights and guidance
as we continue to execute our strategic investments and growth
initiatives to become a profitable, high-growth medical technology
company.”
Ms. Burgess was most recently Chief Financial Officer and Vice
President of Finance for the Americas Region at Medtronic, Inc., a
Fortune 200 global medical device company with more than $30
billion in annual revenues. Prior to this role, Ms. Burgess also
served as Vice President of Customer Care for the Americas and
Western Europe at Medtronic, Inc. and Vice President of Finance for
the Cardiovascular Group’s Sales and Marketing function.
Ms. Burgess earned a Bachelor of Arts in Communication and
Political Science from the University of Michigan and a Master’s in
Business Administration from Ohio State University. Ms. Burgess is
a member of the Board of Directors for Stepan Company.
With Ms. Burgess’ appointment, AngioDynamics’ total number of
directors will increase to nine members.
About AngioDynamics, Inc.
AngioDynamics is a leading, and transformative medical
technology company focused on restoring healthy blood flow in the
body’s vascular system, expanding cancer treatment options and
improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by
talented physicians in fast-growing healthcare markets to treat
unmet patient needs. For more information, visit
www.angiodynamics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724751181/en/
Investor Relations: Stephen Trowbridge 518-795-1408
strowbridge@angiodynamics.com
Media: Saleem Cheeks 518-795-1174
scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
AngioDynamics (NASDAQ:ANGO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024